Reston, VA (September 26, 2025)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
New PSMA-Targeted Therapy Shows Promise in Prostate Cancer Models
Researchers tested a novel therapy, ADVC001, designed to deliver targeted alpha radiation using 212Pb. Laboratory and animal studies demonstrated strong tumor binding, specific cancer cell killing, rapid clearance from healthy tissues, and improved survival compared to standard PSMA therapies, highlighting its potential in advanced prostate cancer treatment.
Ultra-High-Resolution PET Reveals Tiny Structures in the Human Brain
Scientists developed a new PET scanner capable of capturing brain images at nearly 2-µL resolution. In patient studies, this ultra-high-resolution system distinguished small, previously hard-to-see regions such as the subthalamic areas and brainstem nuclei, offering sharper insights into brain function and disease than standard PET/CT.
New PET Tracer Targets Liver Cancer with Safety and Precision
A novel PET tracer, 68Ga-RAYZ-8009, was tested in patients with suspected or confirmed liver cancer. Imaging showed clear whole-body distribution, with kidneys receiving the highest radiation dose. The tracer demonstrated selective targeting of glypican 3 and favorable safety, supporting its potential for improved liver cancer detection.
Combining Radiation Therapies in Advanced Prostate Cancer
A real-world study examined patients receiving both external beam radiotherapy (EBRT) and LuPSMA for metastatic castration-resistant prostate cancer. Most EBRT was palliative, and side effects were comparable to LuPSMA alone, though thrombocytopenia was more common when EBRT was given within three months of LuPSMA. Survival outcomes were similar.
First-in-Human Trial Tests New Alpha Therapy for Thyroid Cancer
Researchers evaluated 211At-NaAt, an alpha-emitting therapy, in patients with advanced thyroid cancer resistant to radioactive iodine. In this dose-escalation study, treatment was generally well tolerated, with some blood-related toxicities at higher doses. Early signs of tumor response and disease stabilization suggest potential for this novel targeted therapy.
Comparing Two Methods to Prepare Patients for Thyroid Cancer Treatment
A study of more than 900 lesions used PET/CT dosimetry to compare thyroid hormone withdrawal (THW) and recombinant human thyroid-stimulating hormone before radioiodine therapy. Results showed higher absorbed radiation doses in metastatic lesions after THW, while thyroid remnants responded similarly with both methods, suggesting preparation choice may influence outcomes
Open-Source Software Advances Nuclear Medicine Dosimetry
Researchers introduced OpenDose3D, a free software platform for personalized radiation dose calculations in nuclear medicine. Built on 3D Slicer, it supports multiple clinical workflows, calibration, and dose modeling. Testing showed excellent accuracy with reference datasets, making it a valuable tool for research, education, and comparing commercial dosimetry systems.
New PET/CT Scan Improves Detection of Overactive Parathyroid Glands
In a study of 174 patients with hyperparathyroidism, 11C-choline PET/CT accurately identified abnormal parathyroid glands with over 90 percent sensitivity and strong predictive value. While results supported its effectiveness in guiding surgery, moderate variation between reviewers highlighted the need for clearer interpretation criteria, especially for ectopic gland localization.
AI Tool Enhances Prognosis Prediction in Prostate Cancer Imaging
Using PSMA PET scans, researchers applied an AI-assisted tracking system (TRAQinform IQ) to monitor tumor changes in patients with advanced prostate cancer receiving radiopharmaceutical therapy. The analysis linked new lesion growth with shorter survival and disappearing lesions with longer survival, highlighting the tool's potential for early treatment response assessment.
Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn .
